货号:A439969
同义名:
ML-9 HCl; ML-9 hydrochloride
ML-9 是一种肌球蛋白轻链激酶(MLCK)抑制剂,可增强紫杉醇的抗癌活性,通过双重抑制 Akt 通路和自噬作用发挥潜在抗癌效果,常用于癌症的研究。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 靶点 |
|
| 描述 | The Ca2+/calmodulin-dependent myosin light-chain kinase (MLCK) pathway is considered the primary regulatory pathway for contraction of airway smooth muscle. ML-9 is a membrane-permeable organic substance that has been identified as an inhibitor of MLCK. ML-9 at a concentration of 30 or 100μM inhibited Ca2+ mobilization induced by a high concentration of K+, methacholine, and thapsigargin in guinea pig tracheal smooth muscle.[2] ML-9 at 30μM reduced the phosphorylation of Akt in lymph node carcinoma of the prostate (LNCaP) cells. Treatment with ML-9 (1 – 50μM, 2 – 24h) also dose- and time-dependently increased the expression level of LC3-II in LNCaP cells. Treatment of LNCaP cells with 30μM ML-9 for 24h significantly induced prostate cancer cell death.[1] |
| 作用机制 | ML-9 is a membrane-permeable organic substance that has been identified as an inhibitor of MLCK, Akt kinase, and stromal interaction molecule 1.[1] |
| Concentration | Treated Time | Description | References | |
| Human neutrophils | 0–117 µM | 1 hour | To evaluate the effect of ML-9 on intracellular calcium concentration in human neutrophils. Results showed that ML-9 enhanced the thapsigargin-induced increase in intracellular calcium levels, suggesting ML-9 may affect calcium flux through mechanisms other than SOCE. | Cells. 2018 Nov 9;7(11):204. |
| LNCaP cells | 30 µM | 12 hours | ML-9 inhibits Akt phosphorylation, reduces mTOR activity, increases LC3-II levels, and induces autophagosome accumulation. | Cell Death Dis. 2014 Apr 24;5(4):e1193. |
| HEK293 cells | 100 µM | 5 minutes | To evaluate the inhibitory effects of ML-9 on SOCE and EYFP-Stim1 rearrangement. Results showed that ML-9 nearly completely inhibited SOCE and prevented the formation of punctate EYFP-Stim1 structures near the plasma membrane. | J Cell Sci. 2008 Mar 15;121(Pt 6):762-72. |
| HEK293 cells | 7.8 µM (IC50) | 5 seconds | ML-9 inhibits TRPC6 channels via a mechanism independent of MLCK activity, acting directly on the TRPC6 channel itself. | Br J Pharmacol. 2007 Sep;152(1):122-31. |
| 3T3-L1 adipocytes | 50 µM | 90 minutes | To investigate the effect of ML-9 on metabolic stress and insulin-stimulated glucose uptake, results showed that ML-9 inhibited azide- and insulin-stimulated glucose uptake. | Biochem J. 1995 Aug 1;309 ( Pt 3)(Pt 3):731-6. |
| Clone9 cells | 50 µM | 90 minutes | To investigate the effect of ML-9 on metabolic stress and insulin-stimulated glucose uptake, results showed that ML-9 inhibited azide- and insulin-stimulated glucose uptake. | Biochem J. 1995 Aug 1;309 ( Pt 3)(Pt 3):731-6. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.77mL 0.55mL 0.28mL |
13.84mL 2.77mL 1.38mL |
27.68mL 5.54mL 2.77mL |
|
| CAS号 | 105637-50-1 |
| 分子式 | C15H18Cl2N2O2S |
| 分子量 | 361.29 |
| SMILES Code | O=S(N1CCNCCC1)(C2=C3C=CC=C(Cl)C3=CC=C2)=O.[H]Cl |
| MDL No. | MFCD00065525 |
| 别名 | ML-9 HCl; ML-9 hydrochloride |
| 运输 | 蓝冰 |
| InChI Key | ZNRYCIVTNLZOGI-UHFFFAOYSA-N |
| Pubchem ID | 108047 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 85 mg/mL(235.27 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 5 mg/mL(13.84 mM) 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1